Zurich Cantonal Bank
BCRX icon

Zurich Cantonal Bank’s BioCryst Pharmaceuticals BCRX Stock Holding History

Zurich Cantonal Bank’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-57,351
Closed -$447K – 2678
2025
Q4 		$447K Buy
+57,351
New +$415K ﹤0.01% 1851

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Zurich Cantonal Bank's BCRX Position: Q1 2026 in Review

Zurich Cantonal Bank opened a new position in BioCryst Pharmaceuticals (BCRX) in Q1 2026: 208,903 shares worth $1.99M. The stake represents ﹤0.01% of the portfolio and ranks #1053 among its holdings. This is a return to the name: Zurich Cantonal Bank previously reported a position in BCRX as recently as Q3 2025.

Zurich Cantonal Bank first reported a position in BCRX in Q3 2015 and has held it in 42 quarters since. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Zurich Cantonal Bank held 208,903 shares of BioCryst Pharmaceuticals worth $1.99M as of Q1 2026.
  • BioCryst Pharmaceuticals was a new Zurich Cantonal Bank position in Q1 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q1 2026, its #1053 holding.
  • Zurich Cantonal Bank first reported a position in BioCryst Pharmaceuticals in Q3 2015 and has held it in 42 quarters since.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Zurich Cantonal Bank's 13F filing for Q1 2026, filed 15 May 2026.